Affordable Access

Publisher Website

Somatic mutation of PTEN in bladder carcinoma

British Journal of Cancer
Nature Publishing Group
Publication Date
DOI: 10.1038/sj.bjc.6690439
  • Regular Article


The tumour suppressor gene PTEN/MMAC1, which is mutated or homozygously deleted in glioma, breast and prostate cancer, is mapped to a region of 10q which shows loss of heterozygosity (LOH) in bladder cancer. We screened 123 bladder tumours for LOH in the region of PTEN. In 53 informative muscle invasive tumours (≥ pT2), allele loss was detected in 13 (24.5%) and allelic imbalance in four tumours (overall frequency 32%). LOH was found in four of 60 (6.6%) informative, non-invasive tumours (pTa/pT1). We screened 63 muscle invasive tumours for PTEN mutations by single-strand conformation polymorphism (SSCP) analysis and for homozygous deletion by duplex quantitative polymerase chain reaction (PCR). Two homozygous deletions were identified but no mutations. Of 15 bladder tumour cell lines analysed, three showed homozygous deletion of all or part of the PTEN gene, but none had mutations detectable by SSCP analysis. Our results indicate that PTEN is involved in the development of some bladder tumours. The low frequency of mutation of the retained allele in tumours with 10q23 LOH suggests that there may be another predominant mechanism of inactivation of the second allele, for example small intragenic deletions, that hemizygosity may be sufficient for phenotypic effect, or that there is another target gene at 10q23. © 1999 Cancer Research Campaign

There are no comments yet on this publication. Be the first to share your thoughts.


Seen <100 times

More articles like this

Somatic mutation of PTEN in bladder carcinoma.

on British Journal of Cancer May 1999

Lack of somatic mutation in the PTEN gene in squam...

on Journal of Dermatological Scie... April 1999

Somatic mutation of PTEN in vulvar cancer.

on Clinical Cancer Research August 2000
More articles like this..